Molecular and Cellular Biochemistry

, Volume 409, Issue 1–2, pp 13–22 | Cite as

Novel protein–protein interactions of TPPII, p53, and SIRT7

  • Jarmila Nahálková


Novel protein–protein interactions of TPPII, SIRT7, and p53 were detected by co-immunoprecipitation using both HeLa cell lysates and the cytoplasmic fraction prepared by fractionation of mouse liver tissue. The interactions were further verified in vivo by in situ proximity ligation assay (PLA) within control HEK293 cells transformed with empty vector, highactTPPII HEK293 cells over-expressing murine TPPII displaying high specific enzymatic activity and in lowactTPPII HEK293 cells over-expressing human TPPII having low specific activity of the enzyme. Besides an abundant cytoplasmic localization of TPPII-p53 interaction signal, the nuclear interactions were also demonstrated. The cytoplasmic interactions were likewise detected between TPPII and SIRT7 in control HEK293 and lowactTPPII HEK293 cells. The interactions of SIRT7 with p53 were confirmed in three HEK293 cell transformants as well. The cytoplasmic occurrence of SIRT7 protein was demonstrated by immunofluorescence, when both nucleolar and cytoplasmic signals were identified within HEK293 cells and primary human fibroblasts. The unique cytoplasmic localization of SIRT7 protein was discussed based on an epitope specificity of N-terminus specific SIRT7 antibodies utilized in the present study compared with C-terminus specific antibodies previously used for nuclear detection of SIRT7 by other authors. The epitope sequence of N-terminal antibodies is occurring in all three splicing variants of SIRT7 compared to the epitope of C-terminal antibody, which is specific exclusively to the splicing variant 1. The cytoplasmic localization of p53 detected by immunofluorescence supported the results from its interactions with TPPII and SIRT7 observed by in situ PLA within model cells. Novel interactions of TPPII, p53, and SIRT7 presented in this study might contribute to the knowledge of the regulatory effects of these proteins on apoptotic pathways and to the understanding mechanisms of aging and lifespan regulation.


TPPII SIRT7 p53 Apoptosis Cellular senescence Aging 



I would like to thank Prof. Birgitta Tomkinson who provided HEK293 transformants and a space in her laboratory. The primary human fibroblasts were kindly provided by “Parkinson Institute Biobank” ( of the Telethon Genetic Biobank Network supported by TELETHON Italy (Project No. GTB07001) and by “Fondazione Grigioni per il Morbo di Parkinson. Mouse liver tissue was provided by Dr. Maria Ringvall from animals, which were sacrificed for other kind of an experimental work covered by her own ethical approval. The experimental work with human fibroblasts was part of the project approved by Regional Ethical Committee (EPN) in Uppsala, Sweden under Registration Number 2014/044. The experimental research was financially supported by Försäkringskassan, O. E. och Edla Johanssons vetenskapliga stiftelse and Stiftelsen Sigurd och Elsa Goljes Minne. The funding sources did not have any role in the experimental design, analysis, and data interpretation or in making publishing decisions.


  1. 1.
    Lévy F, Burri L, Morel S, Peitrequin AL, Lévy N et al (2002) The final N-terminal trimming of a subaminoterminal proline-containing HLA class I-restricted antigenic peptide in the cytosol is mediated by two peptidases. J Immunol 169:4161–4171CrossRefPubMedGoogle Scholar
  2. 2.
    Bålöw R-M, Ragnarsson U, Zetterqvist O (1983) Tripeptidyl aminopeptidase in the extralysosomal fraction of rat liver. J Biol Chem 258:11622–11628PubMedGoogle Scholar
  3. 3.
    Reits E, Neijssen J, Herberts C, Benckhuijsen W, Janssen L (2004) A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity 20:495–506CrossRefPubMedGoogle Scholar
  4. 4.
    York IA, Bhutani N, Zendzian S, Goldberg AL, Rock KL (2006) Tripeptidyl peptidase II is the major peptidase needed to trim long antigenic precursors, but is not required for most MHC class I antigen presentation. J Immunol 177:1434–1443CrossRefPubMedGoogle Scholar
  5. 5.
    Gavioli R, Frisan T, Vertuani S, Bornkamm GW, Masucci MG (2001) C-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells. Nat Cell Biol 3:283–288CrossRefPubMedGoogle Scholar
  6. 6.
    Duensing S, Darr S, Cuevas R, Melquiot N, Brickner AG et al (2010) Tripeptidyl peptidase II is required for c-MYC-induced centriole over duplication and a novel therapeutic target in c-MYC-associated neoplasms. Gen Cancer 1:883–892CrossRefGoogle Scholar
  7. 7.
    Stavroupoulou V, Xie J, Henriksson M, Tomkinson B, Imreh S et al (2005) Mitotic infidelity and centrosome duplication errors in cells overexpressing tripeptidyl-peptidase II. Cancer Res 65:1361–1368CrossRefGoogle Scholar
  8. 8.
    Huai J, Firat E, Nil A, Million D, Gaedicke S et al (2008) Activation of cellular death programs associated with immunosenescence-like phenotype in TPPII knockout mice. Proc Natl Acad Sci USA 105:5177–5182PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Huber K, Superti-Furga G (2011) After the grape rush: sirtuins as epigenetic drug targets in neurodegenerative disorders. Bioorg Med Chem 19:3616–3624CrossRefPubMedGoogle Scholar
  10. 10.
    Vakhrusheva O, Smolka C, Gajawada P, Kostin S, Boettger T et al (2008) Sirt7 increases stress resistance of cardiomyocytes and prevents inflammatory cardiomyopathy in mice. Circ Res 102:703–710CrossRefPubMedGoogle Scholar
  11. 11.
    Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I (2005) Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 16:4623–4635PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Martínez-Redondo P, Santos-Barriopedro I, Vaquero A (2012) A big step for SIRT7, one giant leap for sirtuins in cancer. Cancer Cell 21:719–721CrossRefPubMedGoogle Scholar
  13. 13.
    Nahálková J, Tomkinson B (2014) TPPII, MYBBP1A and CDK2 form a protein-protein interaction network. Arch Biochem Biophys 564:128–135CrossRefPubMedGoogle Scholar
  14. 14.
    Levine AJ, Hu W, Feng Z (2006) The P53 pathway: what questions remain to be explored? Cell Death Differ 13:1027–1036CrossRefPubMedGoogle Scholar
  15. 15.
    Driver JA (2012) Understanding the link between cancer and neurodegeneration. J Geriatr Oncol 3:58–67CrossRefGoogle Scholar
  16. 16.
    Tomkinson B, Hansen M, Cheung WF (1997) Structure-function studies of recombinant murine tripeptidyl-peptidase II: the extra domain which is subject to alternative splicing is involved in complex formation. FEBS Lett 405:277–280CrossRefPubMedGoogle Scholar
  17. 17.
    Tomkinson B, Ni Laoi B, Wellington K (2002) The insert within the catalytic domain of tripeptidyl-peptidase II is important for the formation of the active complex. Eur J Biochem 269:1438–1443CrossRefPubMedGoogle Scholar
  18. 18.
    Garner RC, Miller EC, Miller JA (1972) Liver microsomal metabolism of aflatoxin B1 to a reactive derivative toxic to Salmonella typhimurium TA 1530. Cancer Res 32:2058–2066PubMedGoogle Scholar
  19. 19.
    Söding J (2005) Protein homology detection by HMM–HMM comparison. Bioinformatics 21:951–960CrossRefPubMedGoogle Scholar
  20. 20.
    Waterhouse AM, Procter JB, Martin DMA, Clamp M, Barton GJ (2009) Jalview version 2-a multiple sequence alignment editor and analysis workbench. Bioinformatics 25:1189–1191PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Söderberg O, Gullberg M, Jarvius M, Ridderstråle K, Leuchowius K-J et al (2006) Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 3:995–1000CrossRefPubMedGoogle Scholar
  22. 22.
    Tsai YC, Greco TM, Boonmee A, Miteva Y, Cristea IM (2012) Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription. Mol Cell Proteomics 11:60–76PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Barber MF, Michishita-Kioi E, Xi Y, Tasselli L, Kioi M et al (2012) SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature 487:114–118PubMedCentralPubMedGoogle Scholar
  24. 24.
    Martínez-Redondo P, Santos-Barriopedro I, Vaquero A (2012) A big step for SIRT7, one giant leap for sirtuins in cancer. Cancer Cell 21:719–721CrossRefPubMedGoogle Scholar
  25. 25.
    Rose C, Vargas F, Facchinetti P, Bourgeat P, Bambal RB et al (1996) Characterization and inhibition of a cholecystokinin-inactivating serine peptidase. Nature 380:403–409CrossRefPubMedGoogle Scholar
  26. 26.
    Firat E, Huai J, Saveanu L, Gaedicke S, Aichele P et al (2007) Analysis of direct and cross-presentation of antigens in TPPII knockout mice. J Immunol 179:8137–8145CrossRefPubMedGoogle Scholar
  27. 27.
    Lilling G, Novitsky E, Sidi Y, Bakhanashvili M (2003) p53-associated 35′ exonuclease activity in nuclear and cytoplasmic compartments of cells. Oncogene 22:233–245CrossRefPubMedGoogle Scholar
  28. 28.
    Akaogi K, Ono W, Hayashi Y, Kishimoto H, Yanagisawa J (2013) MYBBP1A suppresses breast cancer tumorigenesis by enhancing the p53 dependent anoikis. BMC Cancer 13:65–78PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Karni-Schmidt O, Zupnick A, Castillo M, Ahmed A, Matos T et al (2008) p53 is localized to a sub-nucleolar compartment after proteasomal inhibition in an energy-dependent manner. J Cell Sci 121:4098–4105CrossRefPubMedGoogle Scholar
  30. 30.
    Preta G, Klark R, Glas R (2009) A role for nuclear translocation of tripeptidyl-peptidase II in reactive oxygen species-dependent DNA damage responses. Biochem Biophys Res Comm 389:575–579CrossRefPubMedGoogle Scholar
  31. 31.
    Vakhrusheva O, Braeuer D, Liu Z, Braun T, Bober E (2008) Sirt7-dependent inhibition of cell growth and proliferation might be instrumental to mediate tissue integrity during aging. J Physiol Pharmacol 59:201–212PubMedGoogle Scholar
  32. 32.
    Owen HR, Elser M, Cheung E, Gersbach M, Kraus L et al (2007) MYBBP1a is a novel repressor of NF-κB. J Mol Biol 366:725–736CrossRefPubMedGoogle Scholar
  33. 33.
    Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr (1998) NF-ΚB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281:1680–1683CrossRefPubMedGoogle Scholar
  34. 34.
    Shay JW, Pereira-Smith OM, Wright WE (1991) A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res 196:33–39CrossRefPubMedGoogle Scholar
  35. 35.
    Itahana K, Dimri G, Campisi J (2001) Regulation of cellular senescence by p53. Eur J Biochem 268:2784–2791CrossRefPubMedGoogle Scholar
  36. 36.
    Donehower LA (2002) Does p53 affect organismal aging? J Cell Physiol 192:23–33CrossRefPubMedGoogle Scholar
  37. 37.
    Nilsson A, Fälth M, Zhang X, Kultima K, Sköld K et al (2009) Striatal alterations of secretogranin-1, somatostatin, prodynorphin, and cholecystokinin peptides in an experimental mouse model of Parkinson disease. Mol Cell Proteomics 8:1094–1104PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of Medical Biochemistry and Microbiology (IMBIM), BMCUppsala UniversityUppsalaSweden

Personalised recommendations